证券代码：600873 证券简称：梅花生物 公告编号：2023-055 梅花生物科技集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 09 月 11 日(星期一)至 09 月 15 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 mhzqb@meihuagrp.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 梅花生物科技集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 19 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上半年的经营成果、财务状况，公司计划于 2023 年 09 月 18 日上午 10:00-11:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说 ...

梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 4 月 8 日、2023 年 4 月 28 日召开了第十届董事会第三次会议和 2023 年第二次临时股 东大会，会议审议通过了《关于以集中竞价交易方式回购公司股份的议案》，公 司于 2023 年 4 月 29 日披露了《梅花生物科技集团股份有限公司关于以集中竞价 交易方式回购股份的回购报告书》，本次回购金额不低于人民币 8 亿元，不超过 人民币 10 亿元，回购股份用于注销，减少注册资本。具体内容详见公司披露在 上海证券交易所网站（www.sse.com.cn）上的相关公告。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关法 律法规的要求，公司应在每个月的前 3 个交易日公告截至上月末的回购进展情 况。现将公司回购股份进展的具体情况公告如下： 2023 年 8 月，公司通过集中竞价交易方式回购股份 1609.29 万股，占公司目 前股本总数(2,943,426,102 股)的 0.55%，购买的最低价格为 8.42 元/股、最高价格 为 8.94 元/股，支付的总金额为人民币 13,923.00 万元。 截至 2023 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥13,588,270,517.23, a decrease of 4.44% compared to ¥14,219,627,182.50 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was ¥1,370,843,964.88, down 46.77% from ¥2,575,258,639.11 in the previous year[16]. - The net cash flow from operating activities was ¥2,270,492,293.32, a decline of 34.52% compared to ¥3,467,226,044.54 in the same period last year[16]. - Basic earnings per share for the first half of 2023 were ¥0.45, down 45.78% from ¥0.83 in the same period last year[17]. - The weighted average return on net assets decreased by 11.91 percentage points to 9.46% from 21.37% in the previous year[17]. - The company reported a net profit excluding non-recurring gains and losses of ¥1,406,493,134.64, a decrease of 44.40% from ¥2,529,570,566.12 in the previous year[16]. - The diluted earnings per share were also ¥0.45, reflecting the same decline of 45.78% compared to the previous year[17]. - The company reported a non-recurring loss of ¥35,649,169.76, primarily due to losses from non-operating income and expenses[18]. - The company achieved a stable revenue performance with key products like xanthan gum and pharmaceutical amino acids driving growth, while feed amino acid product revenue decreased by 16.04% year-on-year to CNY 4.758 billion[32]. Assets and Liabilities - The total assets at the end of the reporting period were ¥24,393,256,825.48, a slight decrease of 0.40% from ¥24,490,222,471.46 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company increased by 5.46% to ¥14,254,255,752.16 from ¥13,516,133,352.77 at the end of the previous year[16]. - The asset-liability ratio at the end of the reporting period was 41.56%, a decrease of 3.25 percentage points from the beginning of the period[31]. - The company's total liabilities were CNY 10,139,001,073.32, down from CNY 10,974,089,118.69, reflecting a decrease of approximately 7.6%[99]. - The total non-current assets increased to CNY 15,553,053,774.35 from CNY 14,577,638,970.15, reflecting an increase of approximately 6.7%[99]. Market and Product Development - The company specializes in amino acid products, including lysine, threonine, tryptophan, and glutamic acid, with a focus on animal nutrition and food flavor optimization[20]. - The company has achieved a full-chain upgrade in synthetic biology, from genome editing to product implementation, enhancing its competitive edge in the industry[20]. - The company is focused on expanding its market presence and enhancing its product portfolio through research and development initiatives[20]. - The company anticipates a continued increase in demand for amino acids due to the reduction of soybean meal in feed formulations, with a target reduction of 0.5 percentage points per year until it reaches below 13% by 2025[23]. - The company is expanding production capacity with new projects, including the Jilin xanthan gum project, which achieved full production in June 2023, enhancing competitive strength[34]. Research and Development - The company applied for 25 new patents in the first half of the year, enhancing its intellectual property portfolio[26]. - Research and development expenses increased to CNY 149,290,010.79 in the first half of 2023, up from CNY 124,531,311.23 in the previous year, marking a growth of 19.8%[105]. - The company has invested in advanced equipment, such as next-generation genome sequencers, to facilitate high-throughput screening and product development[20]. Environmental and Safety Management - The company has implemented safety management measures to mitigate risks associated with production accidents[48]. - The company has invested approximately 200 million yuan in boiler flue gas treatment systems, achieving emissions that are significantly below national standards[61]. - The company has established emergency response plans for environmental pollution incidents, which are filed with local environmental authorities[65]. - The company has faced two environmental administrative penalties due to exceeding odor concentration limits at the factory boundary[67]. Shareholder and Governance Matters - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during this reporting period[3]. - The company completed a share buyback of 450 million yuan in the first half of 2023, reflecting confidence in its future development[31]. - The company’s actual controller and related parties have committed to avoiding any business that may compete with the company’s main operations during their control period, which has been strictly adhered to since July 19, 2010[77]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[78]. Financial Instruments and Accounting Policies - The company classifies financial assets into three categories: those measured at amortized cost, those measured at fair value with changes recognized in other comprehensive income, and those measured at fair value with changes recognized in profit or loss[136]. - Financial assets measured at amortized cost include cash, certain receivables, and debt investments, with interest income recognized using the effective interest method[137]. - The company recognizes impairment for financial assets measured at amortized cost and those classified as fair value through other comprehensive income[143]. - The company assesses expected credit losses for accounts receivable based on historical loss experience and current conditions, predicting future economic conditions[152]. Future Outlook - The company expects revenue growth to continue, projecting a 20% increase for the second half of 2023[131]. - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[102].

证券代码：600873 证券简称：梅花生物 公告编号：2023-051 梅花生物科技集团股份有限公司（以下简称"公司"）第十届董事会第五次会 议于 2023 年 8 月 18 日以现场方式召开，会议应出席董事 5 人，实际出席董事 5 人，会议由董事长王爱军女士主持，公司监事和高级管理人员列席了会议。本次 会议的召开符合《公司法》和《公司章程》的规定。 二、会议审议情况 经出席本次会议的全体董事审议，以投票表决方式全票通过以下议案： 梅花生物科技集团股份有限公司 第十届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、会议召开情况 近年来公司业务规模不断扩大，现有架构设定无法满足日益增长的海外市场 需求，为进一步满足公司拓展国际市场、布局国际贸易和实体业务发展的需要， 公司拟在横琴设立全资子公司。新公司拟定名为横琴梅花控股有限公司（简称"横 琴公司"），法定代表人王爱军，公司类型为有限责任公司（法人独资），出资方 式为货币出资，资金来源为自有资金，经营范围拟定为生物氨基酸产品及其他产 品的生产 ...

证券代码：600873 证券简称：梅花生物 公告编号：2023-052 梅花生物科技集团股份有限公司 关于2023年半年度经营数据公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 3、按地区分： | 地区分布 | 本期营业收入（万元） | | --- | --- | | 国内 | 939,772.42 | | 国外 | 419,054.63 | | 合计 | 1,358,827.05 | 特此公告。 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条、《关于 做好主板上市公司 2023 年半年度报告披露工作的重要提醒》的要求，现将梅花 生物科技集团股份有限公司 2023年半年度经营数据（未经审计）公告如下： 1、按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 444,567.07 | | 饲料氨基酸（赖氨酸、苏氨酸、色氨酸等） | 475,820.72 | | 医药氨基酸（谷氨酰胺、脯氨酸、亮氨酸、异亮氨酸、腺苷等） | 29,991.59 ...

证券代码：600873 证券简称：梅花生物 公告编号：2023-053 梅花生物科技集团股份有限公司 关于 2021 年员工持股计划存续期 即将届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2021 年 1 月 14 日、2021 年 2 月 1 日召开了第九届董事会第十四次会议和 2021 年第一次临时股 东大会，会议审议通过了《关于公司 2021 年员工持股计划（草案）及其摘要的 议案》等相关议案。 公司分别于 2021 年 1 月 14 日、2021 年 2 月 1 日召开了第九届董事会第十 四次会议和 2021 年第一次临时股东大会，会议审议通过了《关于公司 2021 年员 工持股计划（草案）及其摘要的议案》、《关于公司 2021 年员工持股计划管理办 法的议案》、《关于提请股东大会授权董事会全权办理公司员工持股计划相关事项 的议案》等相关议案，具体内容详见公司于 2021 年 1 月 15 日、2021 年 2 月 2 日在上海证券交易 ...

特此公告。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 4 月 8 日、2023 年 4 月 28 日召开了第十届董事会第三次会议和 2023 年第二次临时股 东大会，会议审议通过了《关于以集中竞价交易方式回购公司股份的议案》，公 司于 2023 年 4 月 29 日披露了《梅花生物科技集团股份有限公司关于以集中竞价 交易方式回购股份的回购报告书》，本次回购金额不低于人民币 8 亿元，不超过 人民币 10 亿元，回购股份用于注销，减少注册资本。具体内容详见公司披露在 上海证券交易所网站（www.sse.com.cn）上的相关公告。 现将公司回购股份进展的具体情况公告如下： 证券代码：600873 证券简称：梅花生物 公告编号：2023-050 截至 2023 年 8 月 14 日，公司回购股份 2,033.29 万股，占公司目前股本总数 (2,943,426,102 股)的 0.69%，购买的最低价格为 8.77 元/股、最高价格为 9.15 元/ ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 6,950,072,385.57, representing a year-on-year increase of 3.54%[4] - The net profit attributable to shareholders for Q1 2023 was RMB 800,793,127.47, a decrease of 30.89% compared to the same period last year, primarily due to a decline in gross margin from 26.24% to 19.84%[6] - Basic and diluted earnings per share for Q1 2023 were both RMB 0.26, reflecting a decrease of 29.73% year-on-year[4] - Total revenue for Q1 2023 reached RMB 6,950,072,385.57, an increase of 3.54% compared to RMB 6,712,290,632.48 in Q1 2022[16] - Operating profit for Q1 2023 is approximately ¥945.13 million, down 30.5% from ¥1.36 billion in the same period last year[17] - The net profit for Q1 2023 is approximately ¥800.79 million, a decrease of 30.9% compared to ¥1.16 billion in Q1 2022[17] - Earnings per share for Q1 2023 is ¥0.26, down from ¥0.37 in Q1 2022[17] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 54.20% to RMB 333,494,806.92, mainly due to increased raw material purchases[6] - Cash flow from operating activities for Q1 2023 is approximately ¥333.49 million, a decrease of 54.3% compared to ¥728.21 million in Q1 2022[18] - Cash flow from investing activities shows a net outflow of approximately ¥969.36 million in Q1 2023, slightly higher than the outflow of ¥965.77 million in Q1 2022[19] - Cash flow from financing activities results in a net outflow of approximately ¥217.90 million in Q1 2023, compared to a net outflow of ¥107.41 million in Q1 2022[19] - The company raised approximately ¥640 million in new borrowings in Q1 2023, significantly higher than ¥210 million in Q1 2022[19] - The company's cash and cash equivalents decreased to RMB 3,450,756,112.91 from RMB 4,333,600,657.71 year-over-year[13] - The total cash and cash equivalents at the end of Q1 2023 is approximately ¥3.27 billion, an increase from ¥2.90 billion at the end of Q1 2022[19] Assets and Liabilities - Total assets at the end of Q1 2023 were RMB 24,527,015,822.15, a slight increase of 0.15% from the end of the previous year[4] - The company's total assets amounted to RMB 24,527,015,822.15, slightly up from RMB 24,490,222,471.46 at the end of Q1 2022[15] - Total liabilities increased to RMB 11,599,502,934.70, compared to RMB 10,974,089,118.69 in Q1 2022, reflecting a growth of 5.69%[15] - The company's equity attributable to shareholders decreased to RMB 12,927,512,887.45 from RMB 13,516,133,352.77 in the previous year, a decline of 4.35%[15] - Short-term borrowings rose to RMB 1,324,462,695.04, an increase of 23.6% from RMB 1,070,498,635.74 in Q1 2022[15] - The total non-current liabilities decreased to RMB 3,916,073,176.45 from RMB 4,301,661,573.36, a reduction of 8.93%[15] Shareholder Information - The top shareholder, Meng Qingshan, holds 28.07% of the shares, with a total of 854,103,033 shares[7] - The company completed a share buyback of 99,039,345 shares, accounting for 3.26% of the total share capital at that time, with an average repurchase price of RMB 10.09 per share[11] - The company has initiated a new employee stock ownership plan, purchasing 28,260,800 shares for a total of RMB 295,296,438, representing 0.93% of the total share capital[11] - The company plans to continue implementing share buybacks in accordance with regulatory requirements[11] Strategic Focus and Growth - The increase in operating revenue was mainly driven by growth in sales of flavoring agents and xanthan gum products[6] - The company’s strategic focus includes enhancing its market position through potential mergers and acquisitions, although specific targets were not disclosed[11] - Research and development expenses increased to RMB 70,825,927.68, a rise of 19.93% from RMB 59,037,845.21 in the same period last year[16]

Financial Performance - The company's operating revenue for 2022 was approximately ¥27.94 billion, an increase of 21.14% compared to ¥23.06 billion in 2021[14]. - Net profit attributable to shareholders for 2022 reached approximately ¥4.41 billion, representing an 83.42% increase from ¥2.40 billion in 2021[14]. - The net profit after deducting non-recurring gains and losses was approximately ¥4.22 billion, up 101.69% from ¥2.09 billion in the previous year[14]. - The net cash flow from operating activities for 2022 was approximately ¥5.65 billion, a 51.43% increase from ¥3.73 billion in 2021[14]. - The total assets of the company at the end of 2022 were approximately ¥24.49 billion, reflecting a 16.73% increase from ¥20.98 billion at the end of 2021[14]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥13.52 billion, a 26.64% increase from ¥10.67 billion at the end of 2021[14]. - The company achieved a total revenue of 27.937 billion RMB, representing a year-on-year growth of 21.14%[23]. - The basic earnings per share rose to 1.44 RMB, up 84.62% from 0.78 RMB in 2021[16]. - The weighted average return on equity increased to 35.95%, up 9.18 percentage points from the previous year[24]. - The company maintained a reasonable debt-to-asset ratio of 44.81%[24]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of ¥4.0 per 10 shares, totaling approximately ¥1.22 billion, subject to shareholder approval[2]. - The company declared a cash dividend of RMB 1,216,986,178.8, which accounts for 27.62% of the net profit attributable to shareholders[112]. - The total dividend amount, including cash dividends and share repurchases, reached RMB 2,117,601,589.9, representing 48.06% of the net profit attributable to shareholders[112]. Research and Development - The company introduced a significant number of high-educated talents to strengthen its R&D and engineering teams[23]. - R&D expenses amounted to CNY 829 million, representing a 9.73% increase from the previous year, attributed to increased investment in R&D projects[39]. - The company implemented a dual-driven strategy focusing on technology and management, with significant investments in research and development to maintain industry leadership[26]. - In 2022, the company authorized 27 invention patents, including 2 patents authorized in Japan, and filed 12 new patents[27]. Market and Product Development - The company aims to extend its pharmaceutical amino acids product line to downstream and end products, positioning itself as a leading expert and solution provider in the industry[28]. - The company's market share for adenosine has increased to approximately 70%, while proline's market share has expanded to 60%[29]. - The company has established partnerships with Danone and Nestlé in the special medical food sector, anticipating continued growth in demand[29]. - The company plans to launch a new xanthan gum project in Jilin Baicheng in the first half of 2023[28]. Operational Efficiency - The company maintained an inventory turnover period of approximately 60 days and accounts receivable turnover days of under 10 days, indicating high operational efficiency[36]. - The company has implemented standardized management practices, resulting in a 50% increase in efficiency for finished product and raw material vehicle processing times[30]. - The company achieved a 30% improvement in efficiency for corn transport from factory entry to exit[30]. Environmental and Social Responsibility - The company invested approximately 256.85 million yuan in environmental protection during the reporting period[124]. - The company has established a sustainable development management system and a three-year enhancement plan focusing on ESG (Environmental, Social, and Governance) strategies[81]. - The company is committed to sustainability, with plans to reduce carbon emissions by 20% over the next five years through improved operational efficiencies[88]. - The company has implemented an automatic monitoring system for wastewater and air emissions, ensuring accurate and timely data reporting[133]. Risk Management - The company faces risks from significant fluctuations in raw material prices, particularly corn and coal, which could adversely affect overall gross margins[76]. - The company is exposed to macroeconomic risks, including potential declines in consumer demand due to economic slowdowns or public health crises[77]. - The company is at risk from geopolitical tensions, particularly between the U.S. and China, which could impact its export business[78]. Corporate Governance - The company has established specialized committees under the board, including the remuneration and assessment committee, which is responsible for overseeing executive compensation[99]. - The company has not faced any penalties from securities regulatory agencies in the past three years[95]. - The company conducted a special audit of accounts receivable and accounts payable, leading to a comprehensive review and improvement of internal control processes in sales and procurement[81]. Share Buybacks and Equity Management - The company completed a share buyback of 26,084,878 shares, accounting for 0.84% of the total shares, with an average buyback price of 7.68 CNY per share, totaling 200.20 million CNY[178]. - The company plans to cancel the remaining repurchased shares, reducing its registered capital accordingly[182]. - The total number of shares held by directors and senior management at the end of the reporting period was 148,948,150, a decrease of 990,300 shares compared to the beginning of the year[87]. Audit and Compliance - The audit opinion confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2022[193]. - Revenue recognition was identified as a key audit matter due to inherent risks of manipulation[195]. - The auditor evaluates the appropriateness of accounting policies and the reasonableness of accounting estimates made by management[197].

证券代码：600873 证券简称：梅花生物 公告编号：2023-014 梅花生物科技集团股份有限公司 关于召开2022年度业绩说明会的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 03 月 09 日(星期四)下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 02 日(星期四)至 03 月 08 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 mhzqb@meihuagrp.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 梅花生物科技集团股份有限公司（以下简称"公司"）将于 2023 年 3 月 7 日在上海证券交易所网站（http://www.sse.com.cn/）披露 2022 年年度报告，为便 于广大投资者更全面深入地了解公司 2022 年年度 ...